

## **QIAGEN Digital Insights Expands Biopharma Collaboration with Neo4j to advance Biomedical Data Analysis**

- **New agreement brings leaders in biomedical knowledge solutions and knowledge graph technologies together to aid biopharmaceutical industry in analytics-driven drug discovery**
- **QIAGEN Digital Insights bring over 25 years of expertise in biomedical data content curation for biological discovery**
- **Neo4j brings expertise in knowledge graphs, graph algorithms and ML tools enhanced with GraphRAG (Retrieval Augmented Generation) to enable greater insights and quicker time-to-market for customers**

**Redwood City, California, October 8, 2024** – QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN and the leading provider of bioinformatics software and biomedical knowledge content, today announced the expansion of its strategic partnership with Neo4j®, the world's leading graph database and analytics company. The collaboration will enable Neo4j Graph Database and Graph Data Science capabilities to integrate more deeply with the QIAGEN Biomedical Knowledge Base (BKB) product line, unlocking hidden patterns and relationships in biomedical data, and revealing powerful new insights to advance drug discovery, drug repurposing and translational research.

QDI is known for its deeply curated biomedical knowledge content which power industry leading applications like QIAGEN Ingenuity Pathway Analysis and QIAGEN OmicSoft Lands data. QDI's team of more than 150 data curation scientists in addition to advanced AI approaches have been building this content for more than 25 years.

Neo4j is known for being pioneers in knowledge graphs, algorithms, and machine learning (ML) tools with their GraphRAG technology. By representing data as interconnected nodes and relationships, Neo4j enables businesses to analyze complex patterns, predict future outcomes, and optimize operations in a way that traditional relational databases simply cannot.

Building on existing use of Neo4j graph exports by customers with the QIAGEN BKB, the partnership will explore and develop additional methods and toolsets that work seamlessly with the QIAGEN biomedical knowledge graph. This integration will empower biopharma companies to jumpstart their use of QIAGEN's manually-curated or AI-curated data by easily connecting internal and external data to generate comprehensive data insights and discover novel therapeutic targets.

"Our collaboration with Neo4j has already enabled us to deliver powerful graph-based insights to our customers", said Dominic John, VP and Head of QIAGEN Digital Insights. "By deepening our partnership, we are not only enhancing the usability of our Biomedical Knowledge Base for our customers, but also strategically exploring new methods and toolsets that will work to extend the capabilities of biomedical knowledge graphs. This effort underscores our commitment to providing biopharma companies with the most advanced tools to accelerate their research and development processes."

Sudhir Hasbe, Chief Product Officer at Neo4j, commented: "We are thrilled to expand our partnership with QIAGEN Digital Insights, which has been at the forefront of using graph technology within life sciences. As we develop new ways to integrate and enhance the QIAGEN biomedical knowledge graph, we are confident

that together we will unlock new possibilities for biopharma companies, driving innovation and improving patient outcomes.”

The partnership will focus on enhancing solutions and integrating new technologies that complement each company’s biopharma portfolio. This strategic approach will ensure that biopharma customers have access to the most cutting-edge tools for navigating and analyzing complex biological data.

For more information about this partnership and its impact on the biopharma industry, please join us at [BioTechX Europe 2024 in Basel](#), Switzerland (Neo4j stand #624; QIAGEN stand #328)) or visit the [QIAGEN Digital Insights](#) or [Neo4j](#) websites.

### **About QIAGEN Digital Insights**

QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. QDI has over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3 million profiled patient cases, and over 40 billion scientific data points. The portfolio includes expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. Learn more at <https://digitalinsights.qiagen.com/>.

### **About QIAGEN**

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at <https://www.qiagen.com>.

### **About Neo4j**

Neo4j, the Graph Database & Analytics leader, helps organizations find hidden patterns and relationships across billions of data connections deeply, easily, and quickly. Customers leverage the structure of their connected data to reveal new ways of solving their most pressing business problems, from fraud detection, customer 360, knowledge graphs, supply chain, personalization, IoT, network management, and more – even as their data grows. Neo4j’s full graph stack delivers powerful native graph storage with native vector search capability, data science, advanced analytics, and visualization, with enterprise-grade security controls, scalable architecture, and ACID compliance. Neo4j’s dynamic open-source community brings together over 250,000 developers, data scientists, and architects across hundreds of Fortune 500 companies, government agencies, and NGOs. Visit [neo4j.com](https://neo4j.com).

### **Forward-Looking Statement**

*Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its*

*expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.*

### **Contacts QIAGEN:**

#### **Public Relations**

Thomas Theuringer

+49 2103 29 11826

Lisa Specht

+49 2103 29 14181

e-mail: [pr@QIAGEN.com](mailto:pr@QIAGEN.com)